Cholesterol biosynthesis regulation and protein changes in rat liver following treatment with fluvastatin.
The enzyme 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase is a key regulator in cholesterol biosynthesis and HMG CoA reductase inhibitors (statins) have become a widely prescribed family of lipid lowering agents. Cholesterol synthesis occurs predominantly in liver which is the target organ of statins. We studied the effects of fluvastatin (Lescol), a member of the statin family, on hepatic protein regulation. Male F344 rats treated with 0.8 mg/kg per day fluvastatin or 24 mg/kg per day fluvastatin for 7 days showed treatment-related changes in 58 liver proteins (P<0.005). Major effects were evident in the cholesterol biosynthesis pathway including the induction of enzymes upstream and downstream of the target enzyme HMG CoA reductase. Treatment also triggered alterations in key enzymes of carbohydrate metabolism and was associated with changes in a heterogeneous set of cellular stress proteins involved in cytoskeletal structure, calcium homeostasis and protease activity. The latter set of protein alterations indicates that hepatotoxicity is associated with high-dose treatment. Based on the results it is suggested that HMG-CoA synthase and isopentenyl-diphosphate delta-isomerase may be explored as alternative drug targets and that the induction levels of these enzymes may serve as a measure of potency of individual statin drugs. It is proposed that efficacy and cellular stress markers discovered in this study may be used in a high throughput screen (HTS) assay format to compare efficiently and accurately the therapeutic windows of different members of the statin family.
Steiner
S
S
Large Scale Proteomics Corporation, 9620 Medical Center Drive, Suite 201, Rockville, MD 20850, USA. sandra.steiner@lsp.lsbc.com
Gatlin
C L
CL
Lennon
J J
JJ
McGrath
A M
AM
Seonarain
M D
MD
Makusky
A J
AJ
Aponte
A M
AM
Esquer-Blasco
R
R
Anderson
N L
NL
D000818:Animals; D050260:Carbohydrate Metabolism; D002784:Cholesterol / Q000096:biosynthesis*; D005229:Fatty Acids, Monounsaturated / Q000633:toxicity*; D000077340:Fluvastatin; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000633:toxicity*; D007211:Indoles / Q000633:toxicity*; D050356:Lipid Metabolism; D008099:Liver / Q000187:drug effects* / Q000378:metabolism; D008297:Male; D011506:Proteins / Q000378:metabolism*; D020543:Proteome; D051381:Rats; D011916:Rats, Inbred F344
D005229:Fatty Acids, Monounsaturated; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D007211:Indoles; D011506:Proteins; D020543:Proteome; D000077340:Fluvastatin; D002784:Cholesterol